본문 바로가기
KERD
논문KCI 등재

Immunopathogenesis of childhood idiopathic nephrotic syndrome

정해일
대한소아신장학회 (The Korean Society Of Pediatric Nephrology)|2023.06|Childhood Kidney Diseases (Childhood Kidney diseases)|제27권 제1호|pp. 1-10|DOI 10.3339/ckd.22.042

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

EtiologyAutoimmunityNephrotic syndromeB-lymphocytes
주제분류소아과학

초록

Pediatric nephrotic syndrome (NS) is a clinical syndrome characterized by massive proteinuria, hypoalbuminemia, and generalized edema. Most childhood NS cases are idiopathic (with an unknown etiology). Traditional therapeutic approaches based on immunosuppressive agents largely support the key role of the immune system in idiopathic NS (INS), especially in the steroid-sensitive form. Although most previous studies have suggested the main role of T cell dysfunction and/or the abnormal secretion of certain glomerular permeability factors, recent studies have emphasized the role of B cells since the therapeutic efficacy of B cell depletion therapy in inducing and/or maintaining prolonged remission in patients with INS was confirmed. Furthermore, several studies have detected circulating autoantibodies that target podocyte proteins in a subset of patients with INS, suggesting an autoimmune-mediated etiology of INS. Accordingly, a new therapeutic modality using B cell-depleting drugs has been attempted, with significant effects in a subset of patients with INS. Currently, INS is considered an immune-mediated disorder caused by a complex interplay between T cells, B cells, soluble factors, and podocytes, which may vary among patients. More in-depth investigations of the pathogenic pathways of INS are required for an effective personalized therapeutic approach and to define precise targets for therapeutic intervention.

Abstract

Pediatric nephrotic syndrome (NS) is a clinical syndrome characterized by massive proteinuria, hypoalbuminemia, and generalized edema. Most childhood NS cases are idiopathic (with an unknown etiology). Traditional therapeutic approaches based on immunosuppressive agents largely support the key role of the immune system in idiopathic NS (INS), especially in the steroid-sensitive form. Although most previous studies have suggested the main role of T cell dysfunction and/or the abnormal secretion of certain glomerular permeability factors, recent studies have emphasized the role of B cells since the therapeutic efficacy of B cell depletion therapy in inducing and/or maintaining prolonged remission in patients with INS was confirmed. Furthermore, several studies have detected circulating autoantibodies that target podocyte proteins in a subset of patients with INS, suggesting an autoimmune-mediated etiology of INS. Accordingly, a new therapeutic modality using B cell-depleting drugs has been attempted, with significant effects in a subset of patients with INS. Currently, INS is considered an immune-mediated disorder caused by a complex interplay between T cells, B cells, soluble factors, and podocytes, which may vary among patients. More in-depth investigations of the pathogenic pathways of INS are required for an effective personalized therapeutic approach and to define precise targets for therapeutic intervention.

참고문헌 (100)

  1. Noone DG, "Idiopathic nephrotic syndrome in children", Lancet, 392, pp.61~74 (2018)
  2. Barisoni L, "A proposed taxonomy for the podocytopathies : a reassessment of the primary nephrotic diseases", Clin J Am Soc Nephrol, 2, pp.529~542 (2007)
  3. Shalhoub RJ, "Pathogenesis of lipoid nephrosis : a disorder of T-cell function", Lancet, 2, pp.556~560 (1974)
  4. Lagrue G, "Demonstration in patients with nephrotic syndrome", Biomedicine, 23, pp.37~40 (1975)
  5. Zimmerman SW, "Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation", Clin Nephrol, 22, pp.32~38 (1984)
  6. Koyama A, "A glomerular permeability factor produced by human T cell hybridomas", Kidney Int, 40, pp.453~460 (1991)
  7. Kienzl-Wagner K, "Disease recurrence : the sword of Damocles in kidney transplantation for primary focal segmental glomerulosclerosis", Front Immunol, 10, pp.1669~ (2019)
  8. Hoyer JR, "Recurrence of idiopathic nephrotic syndrome after renal transplantation", Lancet, 2, pp.343~348 (1972)
  9. Laufer J, "Plasma exchange for recurrent nephrotic syndrome following renal transplantation", Transplantation, 46, pp.540~542 (1988)
  10. Dantal J, "Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome", N Engl J Med, 330, pp.7~14 (1994)
  11. Gallon L, "Resolution of recurrent focal segmental glomerulosclerosis after retransplantation", N Engl J Med, 366, pp.1648~1649 (2012)
  12. Kemper MJ, "Transmission of glomerular permeability factor from a mother to her child", N Engl J Med, 344, pp.386~387 (2001)
  13. Kitsou K, "The immunopathogenesis of idiopathic nephrotic syndrome : a narrative review of the literature", Eur J Pediatr, 181, pp.1395~1404 (2022)
  14. Campbell RE, "The immune system and idiopathic nephrotic syndrome", Clin J Am Soc Nephrol, 17, pp.1823~1834 (2022)
  15. Kemper MJ, "Changes of lymphocyte populations in pediatric steroid-sensitive nephrotic syndrome are more pronounced in remission than in relapse", Am J Nephrol, 25, pp.132~137 (2005)
  16. Baris HE, "The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome", Eur J Pediatr, 175, pp.685~693 (2016)
  17. Bhatia D, "Rituximab modulates T-and B-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome", Pediatr Res, 84, pp.520~526 (2018)
  18. Liu LL, "Th17", Treg imbalance in adult patients with minimal change nephrotic syndrome, 2011, pp.139, 314~320
  19. Stachowski J, "Th1", Th2 balance and CD45-positive T cell subsets in primary nephrotic syndrome, 2000, pp.14, 779~785
  20. Park E, "Familial IPEX syndrome : different glomerulopathy in two siblings", Pediatr Int, 57, pp.e59~61 (2015)
  21. Hashimura Y, "Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome", Pediatr Nephrol, 24, pp.1181~1186 (2009)
  22. Chen J, "Immunopathogenesis of idiopathic nephrotic syndrome in children : two sides of the coin", World J Pediatr, 17, pp.115~122 (2021)
  23. Cheung PK, "Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF", J Am Soc Nephrol, 10, pp.1700~1708 (1999)
  24. Lennon R, "Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes", J Am Soc Nephrol, 19, pp.2140~2149 (2008)
  25. Bakker WW, "Altered activity of plasma hemopexin in patients with minimal change disease in relapse", Pediatr Nephrol, 20, pp.1410~1415 (2005)
  26. Wei C, "Modification of kidney barrier function by the urokinase receptor", Nat Med, 14, pp.55~63 (2008)
  27. Wei C, "Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis", Nat Med, 17, pp.952~960 (2011)
  28. Peng Z, "Serum suPAR levels help differentiate steroid resistance from steroid-sensitive nephrotic syndrome in children", Pediatr Nephrol, 30, pp.301~307 (2015)
  29. Meijers B, "The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis", Kidney Int, 85, pp.636~640 (2014)
  30. Sinha A, "Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children", Kidney Int, 85, pp.649~658 (2014)
  31. Delville M, "A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation", Sci Transl Med, 6, pp.256~ (2014)[DOI]
  32. Konigshausen E, "Circulating permeability factors in primary focal segmental glomerulosclerosis : a review of proposed candidates", Biomed Res Int, 2016, pp.3765608~ (2016)
  33. McCarthy ET, "Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis", Clin J Am Soc Nephrol, 5, pp.2115~2121 (2010)
  34. Savin VJ, "Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family", J Immunol Res, 2015, pp.714964~ (2015)
  35. Clement LC, "Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome", Nat Med, 17, pp.117~122 (2011)
  36. Cara-Fuentes G, "Angiopoietin-like-4 and minimal change disease", PLoS One, 12, pp.e0176198~ (2017)
  37. Reiser J, "Induction of B7-1 in podocytes is associated with nephrotic syndrome", J Clin Invest, 113, pp.1390~1397 (2004)
  38. Chugh SS, "New insights into human minimal change disease : lessons from animal models", Am J Kidney Dis, 59, pp.284~292 (2012)
  39. Shimada M, "Minimal change disease: a "two-hit" podocyte immune disorder?", Pediatr Nephrol, 26, pp.645~649 (2011)
  40. Alegre ML, "T-cell regulation by CD28 and CTLA-4", Nat Rev Immunol, 1, pp.220~228 (2001)
  41. Goldwich A, "Podocytes are nonhematopoietic professional antigen-presenting cells", J Am Soc Nephrol, 24, pp.906~916 (2013)
  42. Reiser J, "Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome", J Am Soc Nephrol, 15, pp.2246~2248 (2004)
  43. Wing K, "CTLA-4 control over Foxp3+ regulatory T cell function", Science, 322, pp.271~275 (2008)
  44. Mosser DM, "Interleukin-10 : new perspectives on an old cytokine", Immunol Rev, 226, pp.205~218 (2008)
  45. Cara-Fuentes G, "Minimal change disease: a dysregulation of the podocyte CD80-CTLA-4 axis?", Pediatr Nephrol, 29, pp.2333~2340 (2014)
  46. Garin EH, "Urinary CD80 excretion increases in idiopathic minimal-change disease", J Am Soc Nephrol, 20, pp.260~266 (2009)
  47. Garin EH, "Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis", Kidney Int, 78, pp.296~302 (2010)
  48. Ling C, "Urinary CD80 levels as a diagnostic biomarker of minimal change disease", Pediatr Nephrol, 30, pp.309~316 (2015)
  49. Ling C, "Urinary CD80 excretion is a predictor of good outcome in children with primary nephrotic syndrome", Pediatr Nephrol, 33, pp.1183~1187 (2018)
  50. Yu CC, "Abatacept in B7-1-positive proteinuric kidney disease", N Engl J Med, 369, pp.2416~2423 (2013)
  51. Dado D, "Abatacept efficacy in steroid-resistant minimal-change disease revealed by the speed of proteinuria reduction after the start of abatacept", Clin Nephrol, 89, pp.376~380 (2018)
  52. Minamikawa S, "The utility of urinary CD80 as a diagnostic marker in patients with renal diseases", Sci Rep, 8, pp.17322~ (2018)
  53. Gonzalez Guerrico AM, "Urinary CD80 discriminates among glomerular disease types and reflects disease activity", Kidney Int Rep, 5, pp.2021~2031 (2020)
  54. Benigni A, "Abatacept in B7-1-positive proteinuric kidney disease", N Engl J Med, 370, pp.1261~1263 (2014)
  55. Alachkar N, "Abatacept in B7-1-positive proteinuric kidney disease", N Engl J Med, 370, pp.1263~1264 (2014)
  56. Arase N, "Cellular misfolded proteins rescued from degradation by MHC class II molecules are possible targets for autoimmune diseases", J Biochem, 158, pp.367~372 (2015)
  57. Benz K, "Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy", Pediatr Nephrol, 19, pp.794~797 (2004)
  58. Iijima K, "Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial", Lancet, 384, pp.1273~1281 (2014)
  59. Gauckler P, "Rituximab in adult minimal change disease and focal segmental glomerulosclerosis: what is known and what is still unknown?", Autoimmun Rev, 19, pp.102671~ (2020)
  60. Audard V, "Minimal change nephrotic syndrome and classical Hodgkin's lymphoma : report of 21 cases and review of the literature", Kidney Int, 69, pp.2251~2260 (2006)
  61. Kofman T, "Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders : a retrospective study of 18 cases", Medicine(Baltimore), 93, pp.350~358 (2014)
  62. Chan EY, "Both the rituximab dose and maintenance immunosuppression in steroid-dependent", frequently-relapsing nephrotic syndrome have important effects on outcomes, 2020, pp.97, 393~401
  63. Colucci M, "B-cell dysregulation in idiopathic nephrotic syndrome : what we know and what we need to discover", Front Immunol, 13, pp.823204~ (2022)
  64. Wang CS, "Ofatumumab for the treatment of childhood nephrotic syndrome", Pediatr Nephrol, 32, pp.835~841 (2017)
  65. Dossier C, "A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome", Pediatr Nephrol, 36, pp.1175~1182 (2021)
  66. Shen P, "Antibody-independent functions of B cells : a focus on cytokines", Nat Rev Immunol, 15, pp.441~451 (2015)
  67. Abdel-Hafez M, "Idiopathic nephrotic syndrome and atopy: is there a common link?", Am J Kidney Dis, 54, pp.945~953 (2009)
  68. Cho BS, "Up-regulation of interleukin-4 and CD23", FcepsilonRII in minimal change nephrotic syndrome, 1999, pp.13, 199~204
  69. Kemper MJ, "Combined T-and B-cell activation in childhood steroid-sensitive nephrotic syndrome", Clin Nephrol, 60, pp.242~247 (2003)
  70. Oniszczuk J, "Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults", Nephrol Dial Transplant, 36, pp.609~617 (2021)
  71. Kim AH, "B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement", JCI Insight, 2, pp.e81836~ (2017)
  72. Gbadegesin RA, "HLA-DQA1 and PLCG2 are candidate risk loci for childhood-onset steroid-sensitive nephrotic syndrome", J Am Soc Nephrol, 26, pp.1701~1710 (2015)
  73. Debiec H, "Transethnic, genome-wide analysis reveals immune-related risk alleles and phenotypic correlates in pediatric steroid-sensitive nephrotic syndrome", J Am Soc Nephrol, 29, pp.2000~2013 (2018)
  74. Jia X, "Common risk variants in NPHS1 and TNFSF15 are associated with childhood steroid-sensitive nephrotic syndrome", Kidney Int, 98, pp.1308~1322 (2020)
  75. Ling C, "Altered B-lymphocyte homeostasis in idiopathic nephrotic syndrome", Front Pediatr, 7, pp.377~ (2019)
  76. Ling C, "Decreased circulating transitional B-cell to memory B-cell ratio is a risk factor for relapse in children with steroid-sensitive nephrotic syndrome", Nephron, 145, pp.107~112 (2021)
  77. Colucci M, "B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome", J Am Soc Nephrol, 27, pp.1811~1822 (2016)
  78. Dantal J, "Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome", J Am Soc Nephrol, 9, pp.1709~1715 (1998)
  79. Musante L, "Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome", Clin Exp Immunol, 141, pp.491~499 (2005)
  80. Alachkar N, "Angiotensin antibodies and focal segmental glomerulosclerosis", N Engl J Med, 368, pp.971~973 (2013)
  81. Jamin A, "Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice", J Autoimmun, 89, pp.149~161 (2018)
  82. Sun Y, "The expression and significance of neuronal iconic proteins in podocytes", PLoS One, 9, pp.e93999~ (2014)
  83. Meyer-Schwesinger C, "A new role for the neuronal ubiquitin C-terminal hydrolase-L1(UCH-L1)in podocyte process formation and podocyte injury in human glomerulopathies", J Pathol, 217, pp.452~464 (2009)
  84. Liu Y, "UCH-L1 expression of podocytes in diseased glomeruli and in vitro", J Pathol, 217, pp.642~653 (2009)
  85. Ye Q, "The important roles and molecular mechanisms of annexin A2 autoantibody in children with nephrotic syndrome", Ann Transl Med, 9, pp.1452~ (2021)
  86. Ye Q, "Seven novel podocyte autoantibodies were identified to diagnosis a new disease subgroup-autoimmune podocytopathies", Clin Immunol, 232, pp.108869~ (2021)
  87. Watts AJ, "Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology", J Am Soc Nephrol, 33, pp.238~252 (2022)
  88. Caster DJ, "Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis", Proteomics Clin Appl, 9, pp.1012~1020 (2015)
  89. Chen P, "Annexin A2 as a target endothelial cell membrane autoantigen in Behçet's disease", Sci Rep, 5, pp.8162~ (2015)
  90. Salle V, "Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome", Eur J Intern Med, 23, pp.665~668 (2012)
  91. Hayes MJ, "Regulation of actin dynamics by annexin 2", EMBO J, 25, pp.1816~1826 (2006)
  92. Ye Q, "Autoimmune podocytopathies : a novel sub-group of diseases from childhood idiopathic nephrotic syndrome", J Am Soc Nephrol, 33, pp.653~654 (2022)
  93. Kestila M, "Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome", Mol Cell, 1, pp.575~582 (1998)
  94. Orikasa M, "Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody", J Immunol, 141, pp.807~814 (1988)
  95. Takeuchi K, "New anti-nephrin antibody mediated podocyte injury model using a C57BL", 6 mouse strain, 2018, pp.138, 71~87
  96. Holmberg C, "Congenital nephrotic syndrome and recurrence of proteinuria after renal transplantation", Pediatr Nephrol, 29, pp.2309~2317 (2014)
  97. Kuusniemi AM, "Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type(NPHS1)", Transplantation, 83, pp.1316~1323 (2007)
  98. Gadegbeku CA, "Design of the nephrotic syndrome study network(NEPTUNE)to evaluate primary glomerular nephropathy by a multidisciplinary approach", Kidney Int, 83, pp.749~756 (2013)
  99. Hada I, "A novel mouse model of idiopathic nephrotic syndrome induced by immunization with the podocyte protein Crb2", J Am Soc Nephrol, 33, pp.2008~2025 (2022)
  100. Moller-Kerutt A, "Crumbs2 is an essential slit diaphragm protein of the renal filtration barrier", J Am Soc Nephrol, 32, pp.1053~1070 (2021)

관련 논문AI추천

Circulating Permeability Factors in Idiopathic Nephrotic SyndromeTae Sun Ha대한소아신장학회 · Childhood Kidney Diseases2019 · 제23권 제1호Pathogenesis of Minimal Change Nephrotic Syndrome: A Review of the Underlying Molecular Mechanisms양은미대한소아신장학회 · Childhood Kidney Diseases2019 · 제23권 제1호Antibody Status in Children with Steroid-Sensitive Nephrotic Syndrome고대균, 이경일, 이준성, 한지환, 황자영연세대학교의과대학 · Yonsei Medical Journal2010 · 제51권 제2호Biomarkers Predicting Treatment-Response in Nephrotic Syndrome of Children: A Systematic Review강희경, 안요한, Jiwon M. Lee, Seon Hee Lim대한소아신장학회 · Childhood Kidney Diseases2021 · 제25권 제2호Steroid-sensitive nephrotic syndrome in children: Korean Society of Pediatric Nephrology clinical practice recommendationsCho Heeyeon, Cho Min Hyun, Cho Myung Hyun, Kang Hee Gyung, Kim Jeong Yeon, Lee Hyun Kyung, Lee Joo Hoon, Lee Yeon hee, Park Dong Ah, Park Eujin, Suh Jin-Soon대한소아신장학회 · Childhood Kidney Diseases2025 · 제29권 제3호Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of KoreaJi Yeon Song, Seong Heon Kim, Su Young Kim, Taek Jin Lim대한소아신장학회 · Childhood Kidney Diseases2018 · 제22권 제1호

이 간행물의 다른 논문 (7건)

Tubulopathy: the clinical and genetic approach in diagnosis조희연, Joung Jinwoonpp. 11-18CUBN mutation: a benign genetic cause of proteinuria?Lee Hyun Kyungpp. 19-25Clinical practice pattern on hematuria and proteinuria in children: the report of a survey for the Korean Society of Pediatric NephrologyMin Jeesu, 강희경, Ahn Yo Han, Choi Nayepp. 26-33Short-term safety profile of COVID-19 vaccination in children and adolescents with underlying medical conditions: a prospective cohort studyChoi Nam-Kyong, Choi Naye, Choe Seung-Ah, Choe Young June, 강희경, 신주영, Kim Seong Heon, Ahn Yo Hanpp. 34-39A case report of tubulointerstitial nephritis and uveitis syndrome in children with an unfavorable outcomePark Mun Hyang, Kong Sang I, 천은정pp. 40-45
원문 보기